Methylation Status of the SOCS3 Gene Promoter in H2228 Cells and  EML4–ALK-positive Lung Cancer Tissues

Methylation Status of the SOCS3 Gene Promoter in H2228 Cells and  EML4–ALK-positive Lung Cancer Tissues

Background and objective The EML4-ALK fusion gene is a newly discovered driver gene of non-small cell lung cancer and exhibits special clinical and pathological features. The JAK-STAT signaling pathway, an important downstream signaling pathway of EML4-ALK, is aberrantly sustained and activated in E...

Full description

Bibliographic Details
Main Authors:	Chunlai LIU, Yongwen LI, Yunlong DONG, Hongbing ZHANG, Ying LI, Hongyu LIU, Jun CHEN
Format:	Article
Language:	zho
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2016-09-01
Series:	Chinese Journal of Lung Cancer
Subjects:	Lung neoplasms Echinoderm microtubule-associated-protein-like 4 (EML4) Anaplastic lymphoma kinase (ALK) Suppressor of cytokine signaling 3 (SOCS3) DNA methylation
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2016.09.01

Similar Items

A New Target in Non-small Cell Lung Cancer: EML4-ALK Fusion Gene
by: Huijuan WANG, et al.
Published: (2011-06-01)

Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report
by: Xueqian Wu, et al.
Published: (2020-06-01)

Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung
by: Shafik Hanan Ezzat, et al.
Published: (2015-06-01)

EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation
by: Ying Li, et al.
Published: (2021-06-01)

A case of lung adenocarcinoma harboring <it>EGFR</it> mutation and <it>EML4-ALK</it> fusion gene
by: Tanaka Hisashi, et al.
Published: (2012-11-01)

Clinical Meaning of EML4-ALK Fusion Gene in Non-small Cell Lung Cancer
by: Wei HAN, et al.
Published: (2013-02-01)

EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
by: Sarah R. Sabir, et al.
Published: (2017-09-01)

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
by: Athanasios R Paliouras, et al.
Published: (2020-07-01)

Value of Immunohistochemical Methods in Detecting EML4-ALK Fusion Mutations:  A Meta-analysis
by: Chang LIU, et al.
Published: (2016-01-01)

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
by: Zilan Song, et al.
Published: (2015-01-01)

Refinement of diagnosis and supporting evidence for the use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer
by: Song P, et al.
Published: (2019-04-01)

Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non‐EML4‐ALK rearrangements detected from cerebrospinal fluid: A case report
by: Zhaona Li, et al.
Published: (2020-01-01)

EML4-ALK-positive lung adenocarcinoma presenting an unusual metastatic pattern in a 29-year-old woman who is alive and well in her third year follow up:A case report
by: Fatma Tokat, et al.
Published: (2017-01-01)

Genes of ancient microtubule-stabilizing proteins traveled through pre-Cambrian Echinoidea to advanced life forms of dry land and ended up in the human genome as the fusion oncogenes-oncoproteins eml1/EML1-abl/ABL, and eml4/EML4-alk/ALK
by: J G Sinkovics
Published: (2016-03-01)

Genes of ancient microtubule-stabilizing proteins traveled through pre-Cambrian Echinoidea to advanced life forms of dry land and ended up in the human genome as the fusion oncogenes-oncoproteins eml1/EML1-abl/ABL, and eml4/EML4-alk/ALK
by: JG Sinkovics
Published: (2016-03-01)

Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma
by: Quan Jiang, et al.
Published: (2017-05-01)

Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC
by: Ying Dai, et al.
Published: (2018-01-01)

Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer
by: Wen MM, et al.
Published: (2016-04-01)

Efficacy and Safety of Crizotinib in Advanced or Recurrent  ALK-positive Non-small Cell Lung Cancer
by: Xiaoyan LI, et al.
Published: (2019-08-01)

Coexisting of COX7A2L–ALK, LINC01210–ALK, ATP13A4–ALK and Acquired SLCO2A1–ALK in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report
by: Cai C, et al.
Published: (2020-08-01)

Successful management of a lung cancer patient harbouring both EGFR mutation and EML4-ALK fusion gene with disseminated intravascular coagulation
by: Kohei Fujita, et al.
Published: (2021-01-01)

Analysis of EML4-ALK Gene Fusion Mutation in Patients  with Non-small Cell Lung Cancer
by: Xuzhou WANG, et al.
Published: (2015-02-01)

A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors  and Chemotherapy
by: Jue WANG, et al.
Published: (2021-05-01)

Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report
by: Ling Zhang, et al.
Published: (2018-06-01)

Clinicopathological and Prognostic Significance of the EML4-ALK Translocation and IGFR1, TTF1, Napsin A Expression in Patients with Lung Adenocarcinoma
by: Pınar BULUTAY, et al.
Published: (2021-01-01)

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion
by: Aguado C, et al.
Published: (2018-03-01)

Successful Alectinib Treatment for Carcinoma of Unknown Primary with <i>EML4-ALK</i> Fusion Gene: A Case Report
by: Keiji Sugiyama, et al.
Published: (2021-05-01)

Methodology of Establishing and Identifying NCI-H2228/Crizotinib-resistant Cell Lines In Vitro
by: Di WU, et al.
Published: (2015-06-01)

The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
by: Stephen P. Ducray, et al.
Published: (2019-07-01)

lincROR influences the stemness and crizotinib resistance in EML–ALK+ non-small-cell lung cancer cells
by: Yang Y, et al.
Published: (2018-06-01)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
by: Estela Sánchez‐Herrero, et al.
Published: (2021-09-01)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
by: Hideko Isozaki, et al.
Published: (2015-04-01)

Research Progress in Non-small Cell Lung Cancer  with Concomitant EML4-ALK Fusion Gene and EGFR Gene Mutation
by: Zhu ZENG, et al.
Published: (2011-11-01)

ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report
by: Kai Ou, et al.
Published: (2021-09-01)

Dramatic response to alectinib in an ALK‐positive LCNEC patient with a poor performance status: A case report
by: Kazuki Masuda, et al.
Published: (2021-09-01)

Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer
by: Shuangyan Tan, et al.
Published: (2018-09-01)

EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells
by: Akihiko Miyanaga, et al.
Published: (2021-03-01)

Genomic Profiling Reveals Synchronous Bilateral Lung Adenocarcinomas With Distinct Driver Alterations of EML4-ALK or TPM3-ROS1 Fusion: A Case Report
by: Benxu Tan, et al.
Published: (2019-11-01)

From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
by: Michael T. Werner, et al.
Published: (2017-10-01)

Therapeutic Sequencing in ALK<sup>+</sup> NSCLC
by: Mei Elsayed, et al.
Published: (2021-01-01)